At a glance
A peptide studied for growth hormone secretagogue activity.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Endocrine responses are a major focus of the cited studies. Claims about recovery or body composition need direct clinical outcome evidence in addition to those measurements.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Ipamorelin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3.0 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg | 9 units (0.09 mL) |
| Weeks 5–8 | 200 mcg | 12 units (0.12 mL) |
| Weeks 9–12 | 250 mcg | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously, ideally 30–60 minutes before bedtime on an empty stomach to synergize with natural nocturnal GH secretion[4][3]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Stimulate endogenous growth hormone release to support anabolic processes related to muscle growth, fat metabolism, and tissue repair[1][2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired), followed by a 2–4 week pause to resensitize receptors.
- Dose Range: 100–250 mcg daily with gradual titration; 200 mcg is a common middle-of-the-road dose.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within ~4 weeks.
Suggested daily titration approach.
- Start: 100 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated.
- Target: 200–250 mcg daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous), ideally 30–60 minutes before bedtime.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks, followed by 2–4 week off-cycle.
- Timing: Evening bedtime dosing preferred; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F) for short-term or −20 °C (−4 °F) for long-term storage in dry, dark conditions[9][10].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~4 weeks with bacteriostatic water[11]. For longer storage, freeze aliquots at −20 °C (−4 °F) and avoid repeated freeze–thaw cycles[10].
- Allow vials to reach room temperature before opening to reduce condensation uptake[9].
Injection Technique
General subcutaneous guidance from clinical best-practice resources[6][7][8].
- Clean your hands and work on a clean surface.
- Swab the vial’s rubber stopper and injection site with alcohol; allow to dry.
- Draw the calculated dose into the insulin syringe, eliminating air bubbles.
- Suitable SC injection areas include the abdomen (2 inches from navel), outer thighs, upper outer arms, or flank/hip area[6].
- Pinch a fold of skin between thumb and forefinger; insert the needle at 45–90° into subcutaneous tissue[6][7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- After injection, release the pinched skin and withdraw the needle at the same angle.
- Apply gentle pressure with a clean cotton or alcohol pad; do not rub vigorously.
- Rotate sites systematically with each dose to prevent irritation or tissue damage[6][8].
- Immediately dispose of the used syringe in a proper sharps container[7].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Ipamorelin, 5 mg each):
- 8 weeks ≈ 2 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 05
Research publication
International Journal of Colorectal Disease (PubMed) — Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (2014 Phase II clinical trial) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Source document
Johns Hopkins Arthritis Center — How to Give a Subcutaneous Injection (patient educational resource) (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑ - 07
Public health resource
NCBI Bookshelf — Best practices for injection: asepsis, preparation, and administration techniques (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Source document
Creative Peptides — How Long Do Peptides Last? Peptide Stability & Shelf Life (technical article on peptide stability) (opens in a new tab)www.creative-peptides.com
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.